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Abstract 
Metal-based drugs are largely undeveloped in pharmacology.  One limiting factor is the 
systemic toxicity of metal-based compounds.   A solid-phase, sequestratable delivery agent for 
local delivery of metals could reduce systemic toxicity, facilitating new drug development in this 
nascent area.  Amorphous peroxotitanates (APT) are ion exchange materials with high affinity 
for several heavy metal ions, and have been proposed to deliver or sequester metal ions in 
biological contexts.  In the current study, we tested a hypothesis that APT are able to deliver 
metals or metal compounds to cells.  We exposed fibroblasts (L929) or monocytes (THP1) to 
metal-APT materials for 72 h in vitro, then measured cellular mitochondrial activity (SDH-MTT 
method) to assess the biological impact of the metal-APT materials vs. metals or APT alone.  
APT alone did not significantly affect cellular mitochondrial activity, but all metal-APT materials 
suppressed the mitochondrial activity of fibroblasts (by 30-65% of controls).  The concentration 
of metal-APT materials required to suppress cellular mitochondrial activity was below that 
required for metals alone, suggesting that simple extracellular release of the metals from the 
metal-APT materials was not the primary mechanism of mitochondrial suppression.  In contrast 
to fibroblasts,  no metal-APT material had a measurable effect on THP1 monocyte mitochondrial 
activity, despite potent suppression by metals alone.  This latter result suggested that 
‘biodelivery’ by metal-APT materials may be cell type-specific.  Therefore, it appears that APT 
are plausible solid phase delivery agents of metals or metal compounds to some types of cells 
for potential therapeutic effect.    
 
Key words: drug delivery, heavy metals, cytotoxicity, mitochondrial activity, monocyte  
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1.  Introduction 
The distinctive oxidation-reduction properties of metal ions, combined with their coordination 
chemistries, allow them to serve critical roles in biological structure, catalysis, and transport.   
These properties also make them attractive candidates for novel drugs in medicine, yet because 
of their relatively potent systemic toxicity, only a few metal-based drugs are currently used, most 
notably Au(I)-based drugs to treat rheumatoid arthritis and cis-platinum compounds to treat 
certain cancers.   Even with the success realized with these Au and Pt-based drugs, systemic 
toxicity of these metal-based drugs has severely limited development of other metal-based 
therapeutics.  One promising strategy to mitigate the systemic toxicity of metal-based drugs is 
local delivery of metal ions or metal-based compounds.  In the current study, we extend our 
ongoing work into the suitability of titanate compounds as agents for local delivery of metal ions 
or compounds to cells.    
Monosodium titanates (MST, NaTi2O5H.xH2O) are amorphous metal oxides that strongly 
bind strontium and the actinides (e.g. plutonium, neptunium, and uranium), and this affinity has 
been employed to sequester ionic radionucides from nuclear waste solutions into a solid phase 
[1,2].  A new class of titanate materials, referred to as amorphous peroxotitanates (APT, 
HvNawTi2O5 .xH2O[yHzO2], v + w = 2 and z = 0-2), have recently been synthesized by converting 
the Ti-OH groups in the MST to Ti-O-OH [3-4]; APT have metal sorption characteristics that are 
similar to MST, but have more favorable sorption kinetics [3,4].  The titanium-peroxo species 
imparts a bright yellow color to the APT powder that is retained in aqueous suspension (Fig. 1).  
MST and APT are both synthesized as particulates ranging in size from approximately 0.1 to 10 
µm ([5], Fig. 1).   
In addition to strontium and the actinides, MST and APT have high adsorption capacities for 
Cd(II), Hg(II) and Au(III) [5].  For example, MST has an adsorption capacity of 1.8 µmol-
Cd(II)/µg of MST when ‘loaded’ from water, somewhat less (0.75 µmol/µg) from phosphate 
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buffered saline [5].  Hg(II) and Au(III) also exhibit substantial adsorption capacities (0.90 and 
0.45 µmol/µg in water, respectively) that are dependent on the ionic strength of the loading 
solution.  The adsorption capacities of APT are similar to MST, but the kinetics of APT 
adsorption are faster [3-4], suggesting better efficiency where rapid ion exchange is desirable, 
for example in continuous solid phase separations.   
The biological properties of MST and APT have been explored only in vitro, but both appear 
to have properties favorable for further development for sequestration or delivery of metals in 
biological environments [6].  By themselves, MST and APT particles at concentrations up to 100 
µg/mL have few overt effects on the metabolic activity of monocytes or fibroblasts.  Studies 
estimating cellular metabolic response have been restricted to mitochondrial activity, however 
[5,6].  Neither APT or MST appear to activate monocytes to secrete inflammatory mediators 
despite their particulate nature and small size [6].  Yet, all work in this area is preliminary and 
needs further investigation.   
Recently, our group exposed cells to MST and APT loaded with two gold compounds.  
Because both Au(III) and Auranofin (a Au(I)-organic compound, [7]) suppress mitochondrial 
succinate dehydrogenase (SDH) activity at relatively low (µM) concentrations, we hypothesized 
that APT or MST combined with gold compounds also might expose cells to the gold 
compounds sufficiently to suppress SDH activity.  Such suppression by gold-MST/ATP 
materials was observed [8] and suggests a delivery of gold compounds to the cells, because 
titanates alone had no measurable effect on SDH activity. Our results further suggested that 
APT was more effective at such ‘biodelivery’, that not all cell types respond similarly, and that 
Au(III) and Auranofin differ in the efficiency of the delivery [8].    
The biological effects of gadolinium, palladium, platinum, and mercury compounds have 
been studied extensively (e.g., [9-14]).  Biological concerns about mercury center around its use 
in dental amalgam, its neurotoxicity, and a significant environmental impact [15-18].  Cisplatin is 
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a successful anti-neoplastic drug and because of its success in this application, the biological 
effects of many palladium- and platinum-organic compounds have been investigated in search 
of other anti-cancer agents (e.g., [19]).  Gadolinium compounds are well known radiographic 
imaging/contrast agents in medicine [20-23].  We selected these metals for study with titanates 
because of their biological relevance.   
Our current work tests a hypothesis that APT can deliver Pt, Au, and Hg compounds and 
ions to two types of cells.  We first established the potency of the metals alone as suppressors 
of cellular metabolic (SDH) activity of two cell types, then related the potency of metal-APT 
materials to the nature of the metal and its loading efficiency onto APT.  Our results here 
support further exploration of metal-titanate complexes as novel drug delivery agents for metals 
or metal compounds to cells from a solid phase that is able to be delivered and sequestered 
locally.  Such a strategy may permit delivery of relatively high local concentrations of metals with 
less systemic toxicity.    
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2.  Materials and methods 
2.1  APT Loading, Assessment of Loading 
Palladium, gadolinium, mercury, and platinum compounds were investigated in the current 
study (Table 1).  We focused on amorphous peroxotitanates (APT) vs. monosodium titanates 
(MST) because the former exhibited faster sorption kinetics for exchange with metal species 
such as gold [3,4,6,8].  APT was synthesized from monosodium titanate (Optima Chemical 
Group, LLC Douglas GA) as described previously [8].   
Metal-APT materials for palladium, mercury and platinum compounds were prepared by 
combining 0.25 g of APT suspended in 1.4 g of water having a pH of 6.9, with 10 mL of a 
phosphate buffer saline (PBS) solution containing the desired metal/metal compound (Table 1) 
at ambient temperature for a minimum of 48 h.  The gadolinium-APT material was prepared by 
adding the APT suspension to a pH 3 solution of gadolinium.  The metal-APT materials were 
separated from the parent solutions by centrifugation (RCF = 1200 x g) for 3 min.  The solid 
phases were rinsed quickly with 6 portions of chilled PBS (4° C; pH = 7.4) and stored as moist 
solids with water contents of about 75 wt%.  The Gd-APT sample was first rinsed with 3 portions 
of dilute nitric acid solution (pH 3) followed by 3 portions of the PBS solution.  Complete drying 
of the metal-loaded APT materials was avoided because resuspension of the dried metal-
loaded APT materials proved difficult in cell-culture solutions.  The quantity of metal loaded onto 
the APT loading was determined by analyzing the complexes for metal content by the difference 
in metal concentrations in the solution before and after contact with the APT solids using 
inductively coupled plasma emission spectroscopy (ICP-ES) for all metals except mercury, 
which was measured using cold vapor atomic absorption spectroscopy (CV-AA).  Metal loading 
efficiency was reported as the number of femtomoles (fmol) of each metal per µg of APT.   
 
2.2  Exposure of cells to metal compounds alone or metal-APT materials 
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In these experiments, we focused on monocytes because of their prominent role in 
orchestrating inflammatory responses and role in chronic inflammatory disease, and fibroblasts 
to assess possible applications of APT in connective tissues.  THP1 monocytes (ATCC TIB202, 
American Type Culture Collection, Manassas VA) were cultured in suspension in RPMI 1640 
cell-culture medium (InVitrogen-Gibco, Carlsbad CA) and 10% fetal bovine serum, with 2 
mmol/L glutamine, 100 units/mL penicillin, and 100 µg/mL streptomycin, all at pH 7.2 
(Invitrogen-Gibco).  L929 fibroblasts were cultured in anchorage dependent format in Ham’s F12 
cell-culture medium with 5% fetal bovine serum and glutamine, penicillin, and streptomycin, as 
with THP1 monocytes.   
Cells (250,000 cells/mL for THP1; 5000 cells/cm2 for L929, both in 200 µL) were plated in 
96-well format (n = 8, flat-bottom format for L929, round-bottom format for THP1).  For 
experiments in which the metal compounds were used alone, stock concentrations of metal 
compounds (Table 1) were diluted using sterile PBS and aseptic techniques to prepare a series 
of solutions which would provide a range of concentrations of the metal species when 20 µL 
was added to 200 µL of the cell-culture.  Controls contained no added metal species.  For some 
metal species (Hg(II), Pt(IV), cis(Pt), the initial concentration range that was selected was too 
cytotoxic and experiments were adjusted using lower ranges of concentrations of metal species.  
Cells were incubated for 72 h at 37° C and 5% CO2 in 100% relative humidity.   
For experiments where APT or metal-APT materials were added, aqueous stock solutions 
containing 3000 mg/L of the APT or metal-APT sample were prepared aseptically in sterile PBS, 
then diluted to a series of secondary solutions that would provide final APT concentrations of 
1.0-100.0 µg/mL (n = 8/condition).  Controls contained APT alone or no APT.  As with the THP1, 
L929 fibroblasts were incubated for 72 h at 37° C and 5% CO2 in 100% relative humidity.   
2.3  SDH assay 
After 72 h, cell response to metals alone, APT alone, or metal-APT combinations was 
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assessed by measuring mitochondrial succinate dehydrogenase (SDH) activity using the MTT  
method (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma-Aldrich).  To 
measure SDH activity specifically, the MTT was added to cultures in a balanced salt solution 
containing only disodium succinate as a source of electrons for MTT reduction.   Details of this 
procedure, adjusted for use with titanate suspensions, has been reported previously [5,6].  The 
assay was performed in a solution of 2 molal sodium succinate to focus the assay on 
mitochondrial function.  This focus has been reported as a reasonable overall estimate of 
cellular metabolic function [23].  SDH activity was normalized to controls without metal or APT 
addition, then plotted as a function of metal-APT or metal concentration.  The concentration 
required to suppress SDH activity by 50% in metal-alone experiments was determined 
graphically.  For metal-APT experiments, ANOVA and Tukey post-hoc analyses were used to 
compare the effects of different metal-APT concentrations (α = 0.05).    
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3.  Results 
3.1  Metal-APT loading  
All  metal species in Table 1 were successfully loaded to some degree onto the amorphous 
peroxotitanate (APT) material (Table 2).  The degree of metal loading ranged from a high for 
Pd(II) at 142 fmol/µg of APT to a low for Pt(IV) at 18 fmol/µg.  Gd(III), Hg(II), and cisPt loaded at 
intermediate levels of 78.8, 37.8, and 56.8 fmol/µg-APT, respectively.  The degree of adsorption 
of a metal onto the APT depended on a number of factors including the metal concentration in 
solution, the metal species in solution, the inherent specificity for adsorption of the metal ion or 
compound and the phase ratio used (i.e., ratio of solution volume to mass of APT).  In this study 
we made no attempt to maximize the loading of a metal onto the APT.  For the syntheses of the 
metal-loaded APT materials used in this study, we kept the quantity of APT and phase ratio of 
metal solution and APT constant.  Thus, the metal-APT loadings reflected both the effects of the 
initial metal concentration in solution and the specificity of the APT material for a specific metal 
or metal compound.  For example, about twice as much Gd(III) loaded onto the APT as Hg(II) 
even though the initial Hg(II) concentration was about 70% higher than that of the Gd(III).  The 
higher loading of cisPt onto APT compared to Pt(IV) suggested that the form of the metal played 
an important role in the affinity of the APT to load a particular metal.  
 
3.2  Cellular response to metal compounds alone 
Each of the metal species suppressed succinate dehydrogenase (SDH) activity in a dose-
dependent manner (Figs. 2,3).  However the potency of metal-induced SDH suppression varied 
widely among the metal species.  For example, a concentration 200-300 µM of Gd(III) 
suppressed the SDH activity of THP1 monocytes by 50% vs. no-metal controls (TC50SDH), yet 
the TC50SDH of cisPt was < 1 µM.  The graphically determined TC50SDH values for other metal 
species fell between these extremes (Table 3).  For some metal species such as Gd(III) or 
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Pd(II), there were distinct differences in how THP1 monocytes and L929 fibroblasts responded.  
For example the TC50SDH for THP1 monocytes to Pd(II) was > 300 µM, whereas for L929 
fibroblasts this value was < 100 µM.  Other metal species such as cisPt, Pt(IV), and Hg(II) had 
similar potencies to both cell types.  Overall, SDH suppression induced by these metal species 
appeared sufficient to use it as a measure of biodelivery of peroxotitanates loaded with these 
species.   
 
3.3 Cellular response to metal-APT materials 
For THP1 monocytes there was no evidence of significant SDH suppression by metal-APT 
materials.  Even at the highest loaded APT concentration (100 µg/mL), no statistically significant 
mitochondrial suppression by metal-APT  materials was observed (Fig. 4).  A tendency of Pd(II)-
APT materials to increase SDH activity was suggested, but not confirmed statistically at 100 
µg/mL.  On the other hand, the SDH activity of L929 fibroblasts were significantly suppressed by 
all metal-APT materials in a dose-dependent fashion (Fig. 5).  At the highest concentration of 
APT complexes (100 µg/mL), SDH suppression rang d from 30% (Pd(II)) to 65% (cisPt) (Table 
3).  This suppression strongly suggested that the metal-APT  materials were able to ‘deliver’ the 
metal species in some fashion to affect cell function.   
Note that for all metal species except cisPt, metal-APT materials-induced suppression of 
SDH activity occurred at metal concentrations far below the TC50SDH values required for metal 
species alone (Table 3).  For example, >500 µM of Gd(III) were required to suppress L929 SDH 
activity by 50%, yet a maximum metal delivery of only 7.9 µM for Gd(III)-APT suppressed SDH 
activity by 45%.  These results suggested that the effect of the loaded APT material was not 
simply occurring via extracellular release of the metal species from the loaded material with 
subsequent cellular interaction.  For cisPt, however, the cisPt-APT material seemed to impede 
SDH suppression of cisPt alone (Table 3).   
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4. Discussion 
The primary hypothesis of the current study was that gadolinium, mercury, palladium, or 
platinum compounds could be ‘biodelivered’ to cells via metal-APT materials.  Testing this 
hypothesis required that we determine the dose-response of cells to metal ions alone and  
identify concentrations that altered cell activity.  As a measure of cell activity, we chose 
mitochondrial function (SDH) because it is simpler to measure than many other cell processes, 
yet is central to the appropriate function of the cell.  In the context of the current study, the 
TC50SDH values of Pd(II), Pt(IV), and Hg(II) in Table 3 were in reasonable agreement with those 
reported previously for other cells and conditions (e.g., [24-28]), giving consideration to the 
many variables that influence such studies.  The ability of these metals to suppress 
mitochondrial activity at low (micromolar) concentrations, combined with their affinity for APT 
made them good candidates to assess the biological effects of metal-APT materials vs. APT 
alone.  However, many other endpoints in cell function could be and should be tested in future 
work that assesses the effects of APT materials with or without metal loading.   
The current data extend our previous reports using the Au(I)-organic complex Auranofin 
[8], and support the possibility of loading APT with other metal ions or metal compounds (Table 
2), although the chemical nature of the loaded compound deserves further investigation.  The 
concentrations of solutions used to ‘load’ APT were not the same for all metal compounds, 
ranging from 6,100 µM for cisPt to 27,400 µM for Pd(II) (Table 1).  These different loading 
concentrations resulted from the upper limits of aqueous solubilities of the compounds in PBS.  
To maximize our chances of demonstrating metal delivery to cells, our strategy was to prepare 
metal-loaded APT materials with metal loaded as high as possible; thus, we used the loading 
solutions in Table 1.   
The difference in loading efficiency between Pt(IV) and cisPt  in Table 2 suggests that 
loading might be regulated or optimized by the nature of the coordinating ligands and oxidation 
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state of a metal ion.  Pt(IV) compounds are kinetically inert, whereas Pt(II) compounds are much 
more reactive [29].  Because cisPt features platinum in the +2 oxidation state, reaction of cisPt 
with the peroxotitanate would be expected to be more rapid and therefore proceed to a further 
extent at 48 h than with the Pt(IV).   Thus, the Pt(II) loading onto the APT sorbent was 
approximately a factor of 3 higher than that of Pt(IV) in spite of the fact that the solution 
concentration of Pt(IV) was 2.5 times higher than that of the cisPt (Table 2).    
Suppression of L929 fibroblast SDH activity by metal-APT materials strongly suggested that 
the materials were able to ‘deliver’ the metals to the fibroblasts (Fig. 5).  All metal-APT materials 
exhibited some ability to suppress mitochondrial activity.  Yet, this ability was not strictly 
dependent on the degree of metal loading (Tables 2,3).  For example, the Pd-APT materials, 
which contained the most metal at 142 fmol/µg, suppressed L929 mitochondrial activity the least 
(30%) among the metals tested.  Pt(IV)-APT, which at 18 fmol/µg contained almost a factor of 8 
times lower metal loading than Pd(II)-APT, suppressed mitochondrial activity more than Pd(II)-
APT.  Scrutiny of Tables 2 and 3 also does not support an inverse relationship between loading 
efficiency and ability to affect cellular changes.  Collectively, these observations suggest more 
complex metal-APT interactions with cells.   
With the exception of cisPt, the metal-APT materials exhibited a greater ability to suppress 
L929 mitochondrial activity than would have been predicted from dose-response curves for the 
metals alone.  For example, > 500 µM of Gd(III) was required to suppress L929 mitochondrial 
activity by 50% (Table III). If all of the Gd from the APT-Gd complex was released, the Gd 
concentration would be only 7.9 µM, 60-fold below the TC50 concentration.  Yet, the Gd-APT 
material suppressed mitochondrial activity by 45%.  This trend was true for all metal-APT 
materials except cisPt.  In this latter case, the cisPt-APT was a less potent suppressor of activity 
than predicted by loading.   
The current study focused on the question of whether delivery of metal ions to cells is 
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possible from metal-APT complexes;  given data supporting such biodelivery in fibroblasts (Fig. 
5), future study into the mechanisms of such delivery is strongly suggested. At first glance, 
several mechanisms are consistent with our current data (Fig. 6).  Metal-APT materials could 
have simply released the metals extracellularly with the metal ions subsequently suppressing 
fibroblast SDH activity.  We suggest that this mechanism, although quite plausible, was not the 
major mechanism in force in the current experiments.  As discussed above, the amount of metal 
maximally carried by the APT was insufficient to cause the observed SDH suppression in 
fibroblasts, even if 100% of the metal were released extracellularly (Table 3, Figs. 2,5).   
Although we have not yet assessed metal release for Pt, Pd, or Gd compounds, in past pilot 
studies, we have assessed desorption from Au(III)-APT and AF-APT complexes from 2 h to 21 
days.  No Au release was detected at pH 7.4, the pH of the cell-culture medium, to the level of 
detection of 1 mg/L (ICP-ES).  Collectively these data tentatively imply that the mechanism of 
L929 mitochondrial suppression in the current experiments may not have simply been a function 
of metal released extracellularly from the metal-APT complex.  Rather, our results indicate that 
delivery of the metal involves some form of cell-APT complex interaction (Fig. 6), or a 
combination of extracellular release and cell-APT interactions.  Yet, a role for desorbed metals 
as contributors to the SDH suppression observed in Fig. 5 should not be ignored and given our 
demonstration of some sort of delivery to fibroblasts, should be studied in detail.   
In contrast to the L929 fibroblasts, mitochondrial activity of the THP1 monocytes was 
uniformly unaffected by the metal-APT materials (Fig. 4). This resistance was surprising 
considering that each of the metals or metal compounds alone suppressed mitochondrial 
activity (Fig. 2), albeit sometimes at a higher concentration than for fibroblasts.  These results 
suggest that cell-APT interactions may be cell-type dependent, and that therapeutically, the use 
of metal-APT materials may be somewhat selective to certain cell types in a tissue. 
Alternatively, because the APT complexes are denser than water, the higher susceptibility of the 
anchorage-dependent fibroblasts to the metal-APT particles vs. the monocyte suspensions may 
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have resulted from a relatively inefficient interaction of APT particles with the suspended 
monocytes vs. the fixed fibroblasts at the bottom of the culture wells.  Another less likely 
possibility was that the different cell-culture media caused different extracellular release rates of 
metal, accounting for the lack of THP1 response.  In any case, the lack of ‘toxicity’ of the metal-
APT  materials toward THP1 provides an opportunity to assess the effects of the materials on 
other monocytic functions.  Overall, the differential response of cell types to the metal-APT 
complexes suggests that certain types of cells might be targeted or avoided during APT-
mediated local delivery of metal based drugs.    
 
5.  Conclusions 
Our data suggest that metal-loaded amorphous peroxotitinates (APT) deliver metals to affect 
cellular function of some, but not all types of cells.  This ‘biodelivery’ likely involves a complex 
interaction between the cell and the metal-APT, rather than simply from  extracellular release of 
the metal compound.  Our results here support further study into the use of metal-APT 
complexes as novel delivery vehicles for metal-based ions or compounds that could be 
sequestered by biological or synthetic barriers to reduce the systemic toxicity experienced with 
current metal-based therapeutics.  The current work provides support for investigation into how 
these complexes alter cell behavior (e.g., via extracellular vs. intracellular release), how different 
tissues may react, and identification of the most promising metal-based agents for affecting 
changes in a variety of cellular functions.  
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Figure Legends 
Fig. 1.  Amorphous peroxotitanate (APT).  Upper left:  powder; lower left:  15 wt% aqueous 
suspension; upper right: SEM image, 400x magnification of powder; lower right:  SEM image, 
5030x magnification of powder.   
Fig. 2.   Dose-response curves of THP1 monocytes or L929 fibroblasts to metal ions and 
compounds alone (Table 1).  Cellular succinate dehydrogenase (SDH) activity was measured 
and expressed as a percentage of controls receiving no metal.  The dash horizontal line 
indicates control levels of SDH activity, arbitrarily set to 100%.  Error bars represent standard 
deviations of replicates (n = 8).   
Fig. 3.   Dose-response curves of L929 fibroblasts to Hg(II), CisPt, and Pt(IV) alone (Table 1).  
The results from Fig. 2 were repeated for these metals with a lower concentration range. 
Cellular succinate dehydrogenase (SDH) activity was measured and expressed as a percentage 
of controls receiving no metal.  The dash horizontal line indicates control levels of SDH activity, 
arbitrarily set to 100%.  Error bars represent standard deviations of replicates (n = 8).   
Fig. 4.  THP1 SDH activity in response to added amorphous peroxotitanate (APT)-metal 
complexes (loaded APT, see Table 2) vs. APT alone (red) after 72 h exposure.  Error bars 
indicate standard deviations of n = 8.  There were no statistically significant differences between 
the controls (horizontal dashed line, red line) and addition of the metal complexes (ANOVA, α = 
0.05).   
Fig. 5.   L929 fibroblast SDH activity in response to amorphous peroxotitanate (APT)-metal 
complexes (loaded APT, see Table 2) vs. APT alone (red) after 72 h exposure.  Error bars 
indicate standard deviations of n = 8.  Lower-case letters delineate statistical groupings 
(ANOVA, Tukey post-hoc, α = 0.05).  Horizontal line indicates native cell SDH activity.   
Fig. 6.  Possible mechanism(s) of biodelivery of metal (M) compounds from metal-APT materials 
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to cells.  The mechanism (top) involving pure extracellular release of the metal compound is not 
supported by the data in the current paper (Table 3, Figs. 2 and 5).   
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Table 1:  Metal Compounds, Sources, Metal Loading Concentrations 
Metal 
Species 
 
Source compound 
 
Manufacturer 
Metal loading solution 
conc. (µM) 
Gd(III) Gd(NO3)2
.
6H2O Aldrich Chemical Company, Inc. 
(St. Louis, Mo) 
11,200 
Hg(II) Hg(NO3)2
.
H2O Fisher Scientific  
(Pittsburgh, PA) 
18,900 
Pd(II) PdCl2 Johnson Matthey, Inc.  
(West Chester, PA) 
27,400 
Pt(IV) PtCl4 Johnson Matthey, Inc.  
(West Chester, PA) 
15,100 
cisPt cis-[PtCl2(NH3)2] Alfa-Aesar  
(Ward Hill, MA) 
6,100 
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Table 2: Degree of metal-APT (amorphous peroxotitanate) loading 
  
Metal 
Ion Metal loading solution conc.*  (µM) 
APT loading ** 
(fmol/µg-APT) 
Gd(III) 11,200**** 78.8 (8)*** 
Hg(II) 18,900 37.8 (4) 
Pd(II) 27,400 142 (15) 
Pt(IV) 15,100 18.0 (2) 
cisPt 6,100 56.8 (6) 
* initial metal concentration used to prepare metal-APT materials 
**  based on solution analyses before and after contact with APT 
*** uncertainties calculated using propagation of error techniques 
**** concentration in dilute nitric acid solution (pH 3) 
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Table 3:  Comparison of expected SDH suppression by APT* vs. actual SDH 
suppression.   
 
Metal 
Species 
Max. metal delivery 
from metal-APT** 
(µM)** 
 
TC50SDH*** L929 
(µM) 
Actual metal-APT induced 
SDH Suppression****  
(%) 
Gd(III) 7.9 > 500 45 
Hg(II) 3.8 18 (4) 40 
Pd(II) 14.2 100 (20) 30 
Pt(IV) 1.8 28 (3) 50 
cisPt 5.7 < 1 65 
*  APT = amorphous peroxotitanate 
** based on 100% delivery of 100 µg/mL of loaded APT into 200 µL cell-culture medium.   
***  Concentration in µM required to suppress SDH activity by 50%, based on dose-response curve 
with metals alone, determined graphically from data in Figs 2,3.    
**** Maximum suppression of SDH activity by metal-APT  materials from Fig. 5 (L929) 
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Fig. 1. Amorphous peroxotitanate (APT). Upper left: powder; lower left: 15 wt% aqueous 
suspension; upper right: SEM image, 400x magnification of powder; lower right: SEM image, 5030x 
magnification of powder.  
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Fig. 2. Dose-response curves of THP1 monocytes or L929 fibroblasts to metal ions and compounds 
alone (Table 1). Cellular succinate dehydrogenase (SDH) activity was measured and expressed as a 
percentage of controls receiving no metal. The dash horizontal line indicates control levels of SDH 
activity, arbitrarily set to 100%. Error bars represent standard deviations of replicates (n = 8).  
140x194mm (600 x 600 DPI)  
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Fig. 3. Dose-response curves of L929 fibroblasts to Hg(II), CisPt, and Pt(IV) alone (Table 1). The 
results from Fig. 2 were repeated for these metals with a lower concentration range. Cellular 
succinate dehydrogenase (SDH) activity was measured and expressed as a percentage of controls 
receiving no metal. The dash horizontal line indicates control levels of SDH activity, arbitrarily set to 
100%. Error bars represent standard deviations of replicates (n = 8).  
63x170mm (1200 x 1200 DPI)  
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Fig. 4. THP1 SDH activity in response to added amorphous peroxotitanate (APT)-metal complexes 
(loaded APT, see Table 2) vs. APT alone (red) after 72 h exposure. Error bars indicate standard 
deviations of n = 8. There were no statistically significant differences between the controls 
(horizontal dashed line, red line) and addition of the metal complexes (ANOVA, α = 0.05).  
103x97mm (600 x 600 DPI)  
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Fig. 5. L929 fibroblast SDH activity in response to amorphous peroxotitanate (APT)-metal 
complexes (loaded APT, see Table 2) vs. APT alone (red) after 72 h exposure. Error bars indicate 
standard deviations of n = 8. Lower-case letters delineate statistical groupings (ANOVA, Tukey post-
hoc, α = 0.05). Horizontal line indicates native cell SDH activity.  
103x95mm (600 x 600 DPI)  
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Fig. 6. Possible mechanism(s) of biodelivery of metal (M) compounds from metal-APT materials to 
cells. The mechanism (top) involving pure extracellular release of the metal compound is not 
supported by the data in the current paper (Table 3, Figs. 2 and 5).  
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